File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity

TitleAssociation between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity
Authors
Issue Date1-Feb-2023
PublisherMDPI
Citation
Microorganisms, 2023, v. 11, n. 2, p. 452 How to Cite?
Abstract

Gut microbiota is increasingly recognized to play a pivotal role in various human physiological functions and diseases. Amidst the COVID-19 pandemic, research has suggested that dysbiosis of the gut microbiota is also involved in the development and severity of COVID-19 symptoms by regulating SARS-CoV-2 entry and modulating inflammation. Previous studies have also suggested that gut microbiota and their metabolites could have immunomodulatory effects on vaccine immunogenicity, including influenza vaccines and oral rotavirus vaccines. In light of these observations, it is possible that gut microbiota plays a role in influencing the immune responses to COVID-19 vaccinations via similar mechanisms including effects of lipopolysaccharides, flagellin, peptidoglycan, and short-chain fatty acids. In this review, we give an overview of the current understanding on the role of the gut microbiota in COVID-19 manifestations and vaccine immunogenicity. We then discuss the limitations of currently published studies on the associations between gut microbiota and COVID-19 vaccine outcomes. Future research directions shall be focused on the development of microbiota-based interventions on improving immune response to SARS-CoV-2 infection and vaccinations.


Persistent Identifierhttp://hdl.handle.net/10722/328343

 

DC FieldValueLanguage
dc.contributor.authorNg, HY-
dc.contributor.authorLeung, WK-
dc.contributor.authorCheung, KS-
dc.date.accessioned2023-06-28T04:42:45Z-
dc.date.available2023-06-28T04:42:45Z-
dc.date.issued2023-02-01-
dc.identifier.citationMicroorganisms, 2023, v. 11, n. 2, p. 452-
dc.identifier.urihttp://hdl.handle.net/10722/328343-
dc.description.abstract<p>Gut microbiota is increasingly recognized to play a pivotal role in various human physiological functions and diseases. Amidst the COVID-19 pandemic, research has suggested that dysbiosis of the gut microbiota is also involved in the development and severity of COVID-19 symptoms by regulating SARS-CoV-2 entry and modulating inflammation. Previous studies have also suggested that gut microbiota and their metabolites could have immunomodulatory effects on vaccine immunogenicity, including influenza vaccines and oral rotavirus vaccines. In light of these observations, it is possible that gut microbiota plays a role in influencing the immune responses to COVID-19 vaccinations via similar mechanisms including effects of lipopolysaccharides, flagellin, peptidoglycan, and short-chain fatty acids. In this review, we give an overview of the current understanding on the role of the gut microbiota in COVID-19 manifestations and vaccine immunogenicity. We then discuss the limitations of currently published studies on the associations between gut microbiota and COVID-19 vaccine outcomes. Future research directions shall be focused on the development of microbiota-based interventions on improving immune response to SARS-CoV-2 infection and vaccinations.<br></p>-
dc.languageeng-
dc.publisherMDPI-
dc.relation.ispartofMicroorganisms-
dc.titleAssociation between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity-
dc.typeArticle-
dc.identifier.doi10.3390/microorganisms11020452-
dc.identifier.hkuros344700-
dc.identifier.volume11-
dc.identifier.issue2-
dc.identifier.spage452-
dc.identifier.eissn2076-2607-
dc.identifier.issnl2076-2607-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats